Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency.
A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol. We investigated the patient's serum for all frequent polymorphisms in cytochrome P450 2D6, assuming him to be a poor neuroleptic metabolizer. We will also discuss other potential mechanisms inducing this disturbance and its differential diagnoses.
Neu
Peter
P
Department of Psychiatry, Freie Universität Berlin, Eschenallee 3, 14050 Berlin, Germany. peter.neu@medizin.fu-berlin.de
Seyfert
S
S
Brockmöller
J
J
Dettling
M
M
Marx
P
P
D000328:Adult; D000445:Aldehyde Oxidoreductases / Q000172:deficiency*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D008607:Intellectual Disability / Q000188:drug therapy; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000378:metabolism*; D011110:Polymorphism, Genetic; D050644:Succinate-Semialdehyde Dehydrogenase
D014150:Antipsychotic Agents; D019389:Cytochrome P-450 CYP2D6; D000445:Aldehyde Oxidoreductases; C493643:ALDH5A1 protein, human; D050644:Succinate-Semialdehyde Dehydrogenase; D006220:Haloperidol